Orphelia Pharma

Developer of therapies for treating pediatric neurology, pediatric oncology, and hematology

placeParis, Ile De France, France calendar_todayFounded 2007 groups9 employees language orphelia-pharma.eu

Innovation

2 patent families (2 granted) — focus: Human necessities; filing pace slowing. Cited 51 times.

YearFilings
20171
20191
20202
20211
20231
20241

Social engagement

Social engagement: 2.1K social following, 3 posts in the last 12 months — below the industry typical range.

Investor mix

3 investors on record; lead investors include Initiative OCTALFA.

Investor typeCountShare
Venture capital133%
Bank & private debt133%
Other / undisclosed133%
Coming soon